Announcements Trials
Browse Landscape

Status

No longer available 4Approved for marketing 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 7Expanded_access 6

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 6Myasthenic Syndromes, Congenital 3Nystagmus, Pathologic 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Expanded_access × Amifampridine × Clear all
NCT02189720 2025-03-26

EAP-001

Catalyst Pharmaceuticals, Inc.

Approved for marketing

Nystagmus, Pathologic, Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT00872950 2022-04-11

LEMS

Lahey Clinic

Approved for marketing

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT02012933 2019-12-11

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Oregon Health and Science University

No longer available

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT00704925 2019-10-30

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

University of California, Davis

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT00994916 2019-07-09

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

University of Pittsburgh

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT01378546 2013-07-18

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Columbia University

No longer available

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡